Frost Family of Funds has announced impressive net sales of $383.8 million for the fiscal year ending July 31, 2026. This significant figure highlights the company’s strong performance in attracting new investments and reflects growing investor confidence in its offerings.
The filing, submitted on October 27, 2026, reveals that Frost Family of Funds has reported an aggregate sale price of securities sold amounting to $1.6 billion. Additionally, the company redeemed or repurchased $1.2 billion in securities during the same fiscal year. These numbers suggest a robust demand for their investment products, which may have implications for the wider investment management industry.
Background
Frost Family of Funds is an investment company based in Oaks, Pennsylvania. The firm focuses on managing various investment funds, including the Frost Credit Fund, Frost Growth Equity Fund, Frost Low Duration Bond Fund, and Frost Total Return Bond Fund. The company’s recent filings indicate a proactive approach in managing its assets and responding to market demands.
What the Filing Says
According to the recent SEC filing (accession number 0002048251-26-009130), the company reported an aggregate sale price of securities sold of $1,597,173,163 and an aggregate price of securities redeemed or repurchased of $1,213,383,184. The filing also noted that the total available redemption credits stood at $1,213,383,184, with net sales calculated at $383,789,979.
Impact
This strong performance may affect various stakeholders, including investors, fund managers, and competitors in the investment management sector. As Frost Family of Funds continues to grow its assets under management, it may set a benchmark for other firms in the industry, prompting them to reevaluate their strategies and offerings.
What's Next
The filing does not say what happens next.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






